BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Di Domenico F, Tramutola A, Barone E, Lanzillotta C, Defever O, Arena A, Zuliani I, Foppoli C, Iavarone F, Vincenzoni F, Castagnola M, Butterfield DA, Perluigi M. Restoration of aberrant mTOR signaling by intranasal rapamycin reduces oxidative damage: Focus on HNE-modified proteins in a mouse model of down syndrome. Redox Biol 2019;23:101162. [PMID: 30876754 DOI: 10.1016/j.redox.2019.101162] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Farrell C, Mumford P, Wiseman FK. Rodent Modeling of Alzheimer's Disease in Down Syndrome: In vivo and ex vivo Approaches. Front Neurosci 2022;16:909669. [DOI: 10.3389/fnins.2022.909669] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Cimini FA, Perluigi M, Barchetta I, Cavallo MG, Barone E. Role of Biliverdin Reductase A in the Regulation of Insulin Signaling in Metabolic and Neurodegenerative Diseases: An Update. Int J Mol Sci 2022;23:5574. [PMID: 35628384 DOI: 10.3390/ijms23105574] [Reference Citation Analysis]
3 Pagnotta S, Tramutola A, Barone E, Di Domenico F, Pittalà V, Salerno L, Folgiero V, Caforio M, Locatelli F, Petrini S, Butterfield DA, Perluigi M. CAPE and its synthetic derivative VP961 restore BACH1/NRF2 axis in Down Syndrome. Free Radic Biol Med 2022:S0891-5849(22)00101-0. [PMID: 35283228 DOI: 10.1016/j.freeradbiomed.2022.03.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
4 Ishihara K. The accumulation of copper in the brain of Down syndrome promotes oxidative stress: possible mechanism underlying cognitive impairment. J Clin Biochem Nutr . [DOI: 10.3164/jcbn.21-155] [Reference Citation Analysis]
5 Litwiniuk A, Baranowska-Bik A, Domańska A, Kalisz M, Bik W. Contribution of Mitochondrial Dysfunction Combined with NLRP3 Inflammasome Activation in Selected Neurodegenerative Diseases. Pharmaceuticals (Basel) 2021;14:1221. [PMID: 34959622 DOI: 10.3390/ph14121221] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Perluigi M, Picca A, Montanari E, Calvani R, Marini F, Matassa R, Tramutola A, Villani A, Familiari G, Domenico FD, Butterfield DA, Oh KJ, Marzetti E, Valentini D, Barone E. Aberrant crosstalk between insulin signaling and mTOR in young Down syndrome individuals revealed by neuronal-derived extracellular vesicles. Alzheimers Dement 2021. [PMID: 34812584 DOI: 10.1002/alz.12499] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
7 Barone E, Di Domenico F, Perluigi M, Butterfield DA. The interplay among oxidative stress, brain insulin resistance and AMPK dysfunction contribute to neurodegeneration in type 2 diabetes and Alzheimer disease. Free Radic Biol Med 2021;176:16-33. [PMID: 34530075 DOI: 10.1016/j.freeradbiomed.2021.09.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
8 Gęgotek A, Atalay S, Skrzydlewska E. UV induced changes in proteome of rats plasma are reversed by dermally applied cannabidiol. Sci Rep 2021;11:20666. [PMID: 34667212 DOI: 10.1038/s41598-021-00134-8] [Reference Citation Analysis]
9 Juszczyk G, Mikulska J, Kasperek K, Pietrzak D, Mrozek W, Herbet M. Chronic Stress and Oxidative Stress as Common Factors of the Pathogenesis of Depression and Alzheimer's Disease: The Role of Antioxidants in Prevention and Treatment. Antioxidants (Basel) 2021;10:1439. [PMID: 34573069 DOI: 10.3390/antiox10091439] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
10 Xu Y, Wei L, Tang S, Shi Q, Wu B, Yang X, Zou Y, Wang X, Ao Q, Meng L, Wei X, Zhang N, Li Y, Lan C, Chen M, Li X, Lu C. Regulation PP2Ac methylation ameliorating autophagy dysfunction caused by Mn is associated with mTORC1/ULK1 pathway. Food Chem Toxicol 2021;156:112441. [PMID: 34363881 DOI: 10.1016/j.fct.2021.112441] [Reference Citation Analysis]
11 Ke J, Tian Q, Xu Q, Fu Z, Fu Q. Mitochondrial dysfunction: A potential target for Alzheimer's disease intervention and treatment. Drug Discov Today 2021;26:1991-2002. [PMID: 33962036 DOI: 10.1016/j.drudis.2021.04.025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Perluigi M, Di Domenico F, Barone E, Butterfield DA. mTOR in Alzheimer disease and its earlier stages: Links to oxidative damage in the progression of this dementing disorder. Free Radic Biol Med 2021;169:382-96. [PMID: 33933601 DOI: 10.1016/j.freeradbiomed.2021.04.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
13 Viedma-Poyatos Á, González-Jiménez P, Langlois O, Company-Marín I, Spickett CM, Pérez-Sala D. Protein Lipoxidation: Basic Concepts and Emerging Roles. Antioxidants (Basel) 2021;10:295. [PMID: 33669164 DOI: 10.3390/antiox10020295] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
14 Lanzillotta C, Di Domenico F. Stress Responses in Down Syndrome Neurodegeneration: State of the Art and Therapeutic Molecules. Biomolecules 2021;11:266. [PMID: 33670211 DOI: 10.3390/biom11020266] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
15 Perrelli A, Fatehbasharzad P, Benedetti V, Ferraris C, Fontanella M, De Luca E, Moglianetti M, Battaglia L, Retta SF. Towards precision nanomedicine for cerebrovascular diseases with emphasis on Cerebral Cavernous Malformation (CCM). Expert Opin Drug Deliv 2021;18:849-76. [PMID: 33406376 DOI: 10.1080/17425247.2021.1873273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Zuliani I, Lanzillotta C, Tramutola A, Francioso A, Pagnotta S, Barone E, Perluigi M, Di Domenico F. The Dysregulation of OGT/OGA Cycle Mediates Tau and APP Neuropathology in Down Syndrome. Neurotherapeutics 2021;18:340-63. [PMID: 33258073 DOI: 10.1007/s13311-020-00978-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
17 Rhea EM, Logsdon AF, Banks WA, Erickson ME. Intranasal Delivery: Effects on the Neuroimmune Axes and Treatment of Neuroinflammation. Pharmaceutics 2020;12:E1120. [PMID: 33233734 DOI: 10.3390/pharmaceutics12111120] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
18 Lanzillotta C, Greco V, Valentini D, Villani A, Folgiero V, Caforio M, Locatelli F, Pagnotta S, Barone E, Urbani A, Di Domenico F, Perluigi M. Proteomics Study of Peripheral Blood Mononuclear Cells in Down Syndrome Children. Antioxidants (Basel) 2020;9:E1112. [PMID: 33187268 DOI: 10.3390/antiox9111112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Chen XQ, Salehi A, Pearn ML, Overk C, Nguyen PD, Kleschevnikov AM, Maccecchini M, Mobley WC. Targeting increased levels of APP in Down syndrome: Posiphen-mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model. Alzheimers Dement 2021;17:271-92. [PMID: 32975365 DOI: 10.1002/alz.12185] [Cited by in Crossref: 6] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
20 Lanzillotta C, Di Domenico F, Perluigi M, Butterfield DA. Targeting Mitochondria in Alzheimer Disease: Rationale and Perspectives. CNS Drugs 2019;33:957-69. [PMID: 31410665 DOI: 10.1007/s40263-019-00658-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 11.0] [Reference Citation Analysis]
21 Martínez-Cué C, Rueda N. Signalling Pathways Implicated in Alzheimer's Disease Neurodegeneration in Individuals with and without Down Syndrome. Int J Mol Sci 2020;21:E6906. [PMID: 32962300 DOI: 10.3390/ijms21186906] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
22 Lanzillotta C, Zuliani I, Tramutola A, Barone E, Blarzino C, Folgiero V, Caforio M, Valentini D, Villani A, Locatelli F, Butterfield DA, Head E, Perluigi M, Abisambra JF, Di Domenico F. Chronic PERK induction promotes Alzheimer-like neuropathology in Down syndrome: Insights for therapeutic intervention. Prog Neurobiol 2021;196:101892. [PMID: 32795489 DOI: 10.1016/j.pneurobio.2020.101892] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
23 Rueda Revilla N, Martínez-Cué C. Antioxidants in Down Syndrome: From Preclinical Studies to Clinical Trials. Antioxidants (Basel) 2020;9:E692. [PMID: 32756318 DOI: 10.3390/antiox9080692] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
24 Lanzillotta C, Zuliani I, Vasavda C, Snyder SH, Paul BD, Perluigi M, Di Domenico F, Barone E. BVR-A Deficiency Leads to Autophagy Impairment through the Dysregulation of AMPK/mTOR Axis in the Brain-Implications for Neurodegeneration. Antioxidants (Basel) 2020;9:E671. [PMID: 32727065 DOI: 10.3390/antiox9080671] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
25 Dierssen M, Fructuoso M, Martínez de Lagrán M, Perluigi M, Barone E. Down Syndrome Is a Metabolic Disease: Altered Insulin Signaling Mediates Peripheral and Brain Dysfunctions. Front Neurosci 2020;14:670. [PMID: 32733190 DOI: 10.3389/fnins.2020.00670] [Cited by in Crossref: 12] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
26 Mollo N, Cicatiello R, Aurilia M, Scognamiglio R, Genesio R, Charalambous M, Paladino S, Conti A, Nitsch L, Izzo A. Targeting Mitochondrial Network Architecture in Down Syndrome and Aging. Int J Mol Sci 2020;21:E3134. [PMID: 32365535 DOI: 10.3390/ijms21093134] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
27 Butterfield DA, Mattson MP. Apolipoprotein E and oxidative stress in brain with relevance to Alzheimer's disease. Neurobiol Dis 2020;138:104795. [PMID: 32036033 DOI: 10.1016/j.nbd.2020.104795] [Cited by in Crossref: 33] [Cited by in F6Publishing: 50] [Article Influence: 16.5] [Reference Citation Analysis]
28 Tramutola A, Lanzillotta C, Di Domenico F, Head E, Butterfield DA, Perluigi M, Barone E. Brain insulin resistance triggers early onset Alzheimer disease in Down syndrome. Neurobiol Dis 2020;137:104772. [PMID: 31987911 DOI: 10.1016/j.nbd.2020.104772] [Cited by in Crossref: 20] [Cited by in F6Publishing: 26] [Article Influence: 10.0] [Reference Citation Analysis]
29 Pérez-Sala D, Domingues R. Lipoxidation targets: From basic mechanisms to pathophysiology. Redox Biol 2019;23:101208. [PMID: 31129033 DOI: 10.1016/j.redox.2019.101208] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]